Kezar Life Sciences IncNASDAQ:KZRNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.6825
- TODAY'S CHANGE (%)-0.0117 (-1.6854%)
- Bid / Lots0.6710/ 1
- Ask / Lots0.6980/ 80
- Open / Previous Close0.6905 / 0.6942
- Day Range
- 52 Week Range
- Volume205,605
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KZR |
|---|---|---|
| 09:32 ET | 1331 | 0.6905 |
| 09:36 ET | 300 | 0.6942 |
| 09:41 ET | 1099 | 0.6938 |
| 09:45 ET | 100 | 0.678 |
| 09:48 ET | 400 | 0.68 |
| 09:50 ET | 370 | 0.6801 |
| 09:52 ET | 200 | 0.68 |
| 09:56 ET | 200 | 0.681 |
| 09:57 ET | 100 | 0.681 |
| 09:59 ET | 1453 | 0.68 |
| 10:01 ET | 300 | 0.68 |
| 10:03 ET | 300 | 0.6812 |
| 10:06 ET | 1700 | 0.6813 |
| 10:10 ET | 200 | 0.6815 |
| 10:12 ET | 400 | 0.682 |
| 10:14 ET | 400 | 0.682 |
| 10:15 ET | 200 | 0.6815 |
| 10:17 ET | 1400 | 0.6813 |
| 10:19 ET | 424 | 0.675 |
| 10:21 ET | 100 | 0.675 |
| 10:26 ET | 100 | 0.67855 |
| 10:30 ET | 100 | 0.6742 |
| 10:32 ET | 100 | 0.6742 |
| 10:33 ET | 800 | 0.6799 |
| 10:37 ET | 100 | 0.6804 |
| 10:39 ET | 100 | 0.6769 |
| 10:42 ET | 425 | 0.6839 |
| 10:44 ET | 100 | 0.6825 |
| 10:48 ET | 100 | 0.6744 |
| 10:50 ET | 100 | 0.6825 |
| 10:51 ET | 1276 | 0.6823 |
| 10:53 ET | 2445 | 0.6772 |
| 10:55 ET | 400 | 0.677399 |
| 10:57 ET | 4690 | 0.6774 |
| 11:00 ET | 2216 | 0.6774 |
| 11:02 ET | 2100 | 0.6849 |
| 11:04 ET | 100 | 0.6849 |
| 11:08 ET | 400 | 0.6849 |
| 11:09 ET | 5290 | 0.6849 |
| 11:11 ET | 431 | 0.6848 |
| 11:13 ET | 400 | 0.6824 |
| 11:15 ET | 510 | 0.6827 |
| 11:18 ET | 1000 | 0.6825 |
| 11:20 ET | 100 | 0.6804 |
| 11:22 ET | 400 | 0.6789 |
| 11:24 ET | 400 | 0.6798 |
| 11:26 ET | 1453 | 0.6793 |
| 11:27 ET | 300 | 0.6773 |
| 11:31 ET | 700 | 0.678895 |
| 11:33 ET | 314 | 0.6751 |
| 11:36 ET | 100 | 0.6749 |
| 11:38 ET | 200 | 0.6796 |
| 11:42 ET | 600 | 0.6772 |
| 11:44 ET | 2700 | 0.6793 |
| 11:45 ET | 1199 | 0.678 |
| 11:49 ET | 100 | 0.6749 |
| 11:51 ET | 100 | 0.6757 |
| 11:54 ET | 100 | 0.6763 |
| 11:58 ET | 300 | 0.675 |
| 12:02 ET | 600 | 0.673805 |
| 12:05 ET | 200 | 0.671 |
| 12:07 ET | 200 | 0.671 |
| 12:09 ET | 700 | 0.6726 |
| 12:12 ET | 200 | 0.6741 |
| 12:14 ET | 100 | 0.6712 |
| 12:18 ET | 5358 | 0.675 |
| 12:20 ET | 9482 | 0.678 |
| 12:23 ET | 200 | 0.678 |
| 12:25 ET | 10288 | 0.6787 |
| 12:27 ET | 100 | 0.68035 |
| 12:30 ET | 800 | 0.6834 |
| 12:32 ET | 200 | 0.6872 |
| 12:36 ET | 8700 | 0.6843 |
| 12:39 ET | 504 | 0.6872 |
| 12:41 ET | 100 | 0.68465 |
| 12:45 ET | 300 | 0.6847 |
| 12:48 ET | 200 | 0.6847 |
| 12:52 ET | 685 | 0.6872 |
| 12:54 ET | 300 | 0.6847 |
| 12:59 ET | 1200 | 0.6847 |
| 01:01 ET | 214 | 0.6871 |
| 01:06 ET | 100 | 0.6838 |
| 01:08 ET | 200 | 0.6838 |
| 01:10 ET | 1100 | 0.68395 |
| 01:12 ET | 143 | 0.6855 |
| 01:14 ET | 3500 | 0.6801 |
| 01:15 ET | 300 | 0.6818 |
| 01:17 ET | 400 | 0.68 |
| 01:21 ET | 200 | 0.6739 |
| 01:24 ET | 200 | 0.6758 |
| 01:26 ET | 433 | 0.6753 |
| 01:28 ET | 200 | 0.6761 |
| 01:32 ET | 200 | 0.6761 |
| 01:33 ET | 200 | 0.6761 |
| 01:35 ET | 800 | 0.6772 |
| 01:37 ET | 200 | 0.6772 |
| 01:39 ET | 200 | 0.6773 |
| 01:44 ET | 100 | 0.6779 |
| 01:46 ET | 200 | 0.6795 |
| 01:48 ET | 388 | 0.6794 |
| 01:50 ET | 300 | 0.6795 |
| 01:51 ET | 100 | 0.6795 |
| 01:53 ET | 200 | 0.6794 |
| 01:55 ET | 1200 | 0.6795 |
| 02:00 ET | 200 | 0.6795 |
| 02:02 ET | 500 | 0.6795 |
| 02:04 ET | 625 | 0.6795 |
| 02:06 ET | 200 | 0.6795 |
| 02:08 ET | 400 | 0.6795 |
| 02:09 ET | 300 | 0.6795 |
| 02:11 ET | 300 | 0.6795 |
| 02:13 ET | 200 | 0.6795 |
| 02:15 ET | 200 | 0.6794 |
| 02:18 ET | 1119 | 0.6794 |
| 02:20 ET | 297 | 0.6795 |
| 02:22 ET | 200 | 0.6794 |
| 02:24 ET | 2130 | 0.6794 |
| 02:26 ET | 200 | 0.6789 |
| 02:27 ET | 200 | 0.6791 |
| 02:29 ET | 473 | 0.6793 |
| 02:31 ET | 100 | 0.6793 |
| 02:33 ET | 13866 | 0.679 |
| 02:36 ET | 100 | 0.6792 |
| 02:38 ET | 700 | 0.67925 |
| 02:40 ET | 1041 | 0.67925 |
| 02:42 ET | 6447 | 0.67935 |
| 02:45 ET | 500 | 0.6793 |
| 02:49 ET | 300 | 0.6794 |
| 02:51 ET | 1062 | 0.6794 |
| 02:54 ET | 529 | 0.6794 |
| 02:56 ET | 300 | 0.6795 |
| 03:00 ET | 400 | 0.6797 |
| 03:02 ET | 200 | 0.6826 |
| 03:05 ET | 500 | 0.6825 |
| 03:07 ET | 400 | 0.6825 |
| 03:09 ET | 100 | 0.6826 |
| 03:12 ET | 100 | 0.6825 |
| 03:14 ET | 2328 | 0.6857 |
| 03:16 ET | 1300 | 0.6857 |
| 03:18 ET | 3835 | 0.693 |
| 03:21 ET | 200 | 0.6919 |
| 03:23 ET | 100 | 0.69 |
| 03:27 ET | 300 | 0.69 |
| 03:30 ET | 605 | 0.6905 |
| 03:32 ET | 200 | 0.6883 |
| 03:34 ET | 100 | 0.6861 |
| 03:36 ET | 200 | 0.6861 |
| 03:38 ET | 500 | 0.6883 |
| 03:39 ET | 800 | 0.6861 |
| 03:41 ET | 5676 | 0.6876 |
| 03:43 ET | 522 | 0.6861 |
| 03:45 ET | 100 | 0.685 |
| 03:48 ET | 100 | 0.685 |
| 03:50 ET | 550 | 0.685 |
| 03:52 ET | 636 | 0.685 |
| 03:54 ET | 1183 | 0.68 |
| 03:56 ET | 300 | 0.68 |
| 03:57 ET | 1721 | 0.6812 |
| 03:59 ET | 1863 | 0.6825 |
Jun 7, 2024
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4), from 5:59PM ET on Friday Jun 07, 2024 by Dow Jones
5:59PM ET on Friday Jun 07, 2024 by Dow Jones
May 29, 2024
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones
4:01PM ET on Wednesday May 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kezar Life Sciences Inc | 51.7M | -0.5x | --- |
LAVA Therapeutics NV | 60.5M | -2.2x | --- |
DURECT Corp | 48.4M | -1.9x | --- |
BioLine RX Ltd | 54.9M | -0.9x | --- |
Curis Inc | 51.9M | -0.9x | --- |
Atara Biotherapeutics Inc | 65.6M | -0.2x | --- |
Company Information
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Contact Information
- Headquarters
- 4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
- Phone
- 650-822-5600
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Graham Cooper
- Director
- Christopher Kirk
- Chief Financial Officer
- Marc Belsky
- Chief Business Officer
- Nick Mordwinkin
- Chief Legal Officer
- Mark Schiller
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $50.5M |
|---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 72.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.29 |
EPS | $-1.40 |
Book Value | $2.58 |
P/E Ratio | -0.5x |
Price/Sales (TTM) | 7.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,591.77% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
